<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>25(1)</volume><submitter>Hatletvedt ND</submitter><funding>University of Bergen</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Functional polymorphisms in the MDM2 promoters have been linked to cancer risk and several non-malignant conditions. Their potential role in bone marrow function during chemotherapy is largely unknown.&lt;h4>Methods&lt;/h4>We investigated the potential associations between genotypes of MDM2 SNP309 (rs2279744), SNP285 (rs117039649) and del1518 (rs3730485) and neutrophil counts in breast cancer patients receiving neoadjuvant sequential epirubicin and docetaxel, with additional G-CSF, in the DDP-trial (NCT00496795). We applied longitudinal ratios, post vs. pre-treatment, of neutrophil counts as our main measure. Differences by genotypes were tested by Jonckheere-Terpstra test for ranked alternatives, while dominant and recessive models were tested by Mann-Whitney U test, and addi</pubmed_abstract><journal>BMC cancer</journal><pagination>308</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11843751</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.</pubmed_title><pmcid>PMC11843751</pmcid><pubmed_authors>Lonning PE</pubmed_authors><pubmed_authors>Geisler J</pubmed_authors><pubmed_authors>Aas T</pubmed_authors><pubmed_authors>Engebrethsen C</pubmed_authors><pubmed_authors>Hatletvedt ND</pubmed_authors><pubmed_authors>Geisler S</pubmed_authors><pubmed_authors>Knappskog S</pubmed_authors><pubmed_authors>Gansmo LB</pubmed_authors></additional><is_claimable>false</is_claimable><name>The impact of functional MDM2-polymorphisms on neutrophil counts in breast cancer patients during neoadjuvant chemotherapy.</name><description>&lt;h4>Background&lt;/h4>Functional polymorphisms in the MDM2 promoters have been linked to cancer risk and several non-malignant conditions. Their potential role in bone marrow function during chemotherapy is largely unknown.&lt;h4>Methods&lt;/h4>We investigated the potential associations between genotypes of MDM2 SNP309 (rs2279744), SNP285 (rs117039649) and del1518 (rs3730485) and neutrophil counts in breast cancer patients receiving neoadjuvant sequential epirubicin and docetaxel, with additional G-CSF, in the DDP-trial (NCT00496795). We applied longitudinal ratios, post vs. pre-treatment, of neutrophil counts as our main measure. Differences by genotypes were tested by Jonckheere-Terpstra test for ranked alternatives, while dominant and recessive models were tested by Mann-Whitney U test, and addi</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Feb</publication><modification>2026-06-01T13:01:39.344Z</modification><creation>2025-04-04T01:12:05.729Z</creation></dates><accession>S-EPMC11843751</accession><cross_references><pubmed>39979836</pubmed><doi>10.1186/s12885-025-13675-2</doi></cross_references></HashMap>